Developer docs
API playgroundTry for free, no card

Search company profiles

SIGA Technologies

Full company profile

uuid000527p

Namestring
SIGA Technologies
Legal namestring
SIGA Technologies, Inc.
Websiteurl
siga.com
Company typeenum
Public
Founded yearint
1995
Descriptiontext

SIGA Technologies is a publicly traded (NASDAQ: SIGA) specialty pharmaceutical company developing antiviral therapeutics for orthopoxvirus infections, with TPOXX (tecovirimat) as its sole commercial asset. TPOXX is a small-molecule antiviral that inhibits the VP37 envelope protein found on all orthopoxviruses, preventing viral particles from exiting infected cells and allowing the immune system to clear the virus. The drug was developed under the FDA's Animal Rule pathway because human efficacy trials are ethically impossible for eradicated diseases, and received Orphan Drug and Fast Track Designation; TPOXX was the first FDA-approved antiviral for smallpox (2018) and is approved across the U.S., Canada, EU/UK, and Japan under the brands TPOXX, Tecovirimat SIGA, and TEPOXX. Pipeline extensions include a post-exposure prophylaxis indication (DoD-funded) and a pediatric liquid suspension (BARDA-funded).

SIGA operates as a biodefense and public health company with a direct-to-government go-to-market model. Revenue is generated almost entirely through negotiated procurement contracts with national governments and their biodefense agencies, principally BARDA and the U.S. Strategic National Stockpile under Project BioShield, the U.S. Department of Defense, and international government customers across more than 30 countries. FY2025 revenue was approximately $95 million (down from ~$139M in 2024), with $88M in product sales, $23.3M in net income, and a $155M cash position with no debt; product launches are regulatory events rather than commercial marketing efforts. The company's economics are driven by multi-year procurement cycles, special cash dividends, and incremental development funding, with corporate operations in New York and R&D in Corvallis, Oregon, and a lean headcount of approximately 50 employees.

Short descriptiontext

SIGA Technologies is a publicly traded pharmaceutical company that develops TPOXX (tecovirimat), the first FDA-approved antiviral for smallpox, and sells it primarily through government procurement contracts with BARDA, the U.S. Department of Defense, and biodefense agencies in 30+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
smallpox antiviral treatment, biodefense medical countermeasures, orthopoxvirus therapeutics, government pharmaceutical procurement, antiviral drug development
Industry4 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYBPADAIAB
Immunization & Vaccine Delivery Programs
SECONDARYHLAJAHAK
Funding, Reimbursement & Vaccines-for-Children (VFC)/Public Purchase Programs
Healthcare & Life Sciences/Public Health, Government & Regulators/Immunization Programs & Vaccine Administration
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals (Antiviral Therapeutics)
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1U.S. Government Procurement
TypeOne Time License
Description

Primary revenue source from U.S. government contracts, particularly BARDA. The company delivered remaining BARDA orders worth $26 million in 2026, with development funding of $27 million added during 2025.

seekingalpha.com
2International Government Sales
TypeOne Time License
Description

Product sales to international governments and NGOs across 30+ countries. In January 2026, the company received a $13 million procurement order from an Asia Pacific customer under a multi-year contract.

siga.com
3Special Cash Dividends
TypeTransaction Fee
Description

The company distributes special cash dividends to shareholders, having declared $0.60 per share dividend payable in April 2026, consistent with prior year distributions.

benzinga.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Operations, Technology or R&D, Personnel, Marketing or Sales
Pricing details1 tier
1Government procurement contracts - pricing negotiated through government contracting processes
ModelOtherBilling cadenceMulti-year contract
Notes

TPOXX is procured by government agencies including the Strategic National Stockpile (SNS) under Project BioShield. Pricing is determined through government procurement processes rather than publicly listed pricing.

siga.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1TPOXX® (tecovirimat)
Description

First FDA-approved antiviral treatment for smallpox; available in oral and IV formulations. Treats smallpox, mpox, cowpox, and vaccinia complications in approved markets.

siga.com
Core offering1 text field

SIGA Technologies develops and commercializes TPOXX (tecovirimat), the first FDA-approved antiviral for the treatment of smallpox, available in oral capsule and intravenous formulations. The company also develops pipeline indications including post-exposure prophylaxis (PEP) and a pediatric liquid suspension formulation, with development funded by U.S. government agencies such as BARDA and the Department of Defense.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over $1 billion in cumulative government procurement orders
+3 more records
Product overview1 text field

SIGA Technologies operates a single commercial product franchise: TPOXX (tecovirimat), a highly targeted antiviral that prevents orthopoxvirus particles from exiting infected cells. The franchise includes two approved formulations—Oral TPOXX capsules (FDA approved 2018) and TPOXX Injection IV (FDA approved 2018)—marketed under regional brand names: Tecovirimat SIGA in the EU/UK and TEPOXX in Japan. SIGA is advancing pipeline development for post-exposure prophylaxis (PEP) indication and a pediatric liquid suspension formulation for children weighing under 13 kg, both funded in partnership with U.S. government agencies (DoD and BARDA).

Product and service4 records
1TPOXX (Oral Tecovirimat Capsules)
CategoryAntiviral Pharmaceutical
Description

First FDA-approved oral antiviral for the treatment of smallpox and related orthopoxvirus infections in adults and pediatric patients weighing at least 13 kg. Marketed under regional brand names Tecovirimat SIGA in the EU and TEPOXX in Japan.

2TPOXX Injection (IV)
CategoryAntiviral Pharmaceutical
Description

Intravenous formulation of tecovirimat approved by the FDA for the treatment of smallpox in patients weighing at least 3 kg who cannot swallow oral capsules.

3TPOXX Post-Exposure Prophylaxis (PEP)
CategoryPipeline / Investigational Indication
Description

Investigational use of TPOXX as a post-exposure prophylaxis for adults exposed to smallpox, in development with U.S. Department of Defense funding and support.

4TPOXX Pediatric Liquid Suspension
CategoryPipeline / Investigational Formulation
Description

Oral liquid suspension formulation of TPOXX being developed for the treatment of smallpox in pediatric patients weighing less than 13 kg, funded in collaboration with BARDA.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Primary strategic partner providing funding and support for TPOXX development. BARDA has supported advanced development of TPOXX under the U.S. Department of Health and Human Services. In 2025, the BARDA contract was modified to add $27 million in development funding. Remaining orders worth $26 million expected to be delivered in 2026.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner funding and supporting the post-exposure prophylaxis (PEP) development program for TPOXX. The DoD collaboration focuses on developing TPOXX as a treatment for adults exposed to smallpox.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

SIGA collaborates with healthcare professionals, governments, and communities to minimize the spread and impact of infectious disease outbreaks. The company has established partnerships with over 30 countries and numerous organizations for smallpox outbreak response.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Regulatory partnership for TPOXX development under the FDA's Animal Rule pathway. FDA granted TPOXX Fast Track Designation and Orphan Drug Designation. TPOXX was the first FDA-approved antiviral for smallpox treatment.

5Strategic National Stockpile (SNS)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The U.S. government has relied on TPOXX treatment for over a decade to equip the Strategic National Stockpile against potential smallpox outbreaks under Project BioShield.

siga.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Sanofi operates a global vaccines franchise and has biodefense and public health partnerships across multiple governments, addressing overlapping stockpiling customers in smallpox, mpox, and broader infectious-disease preparedness alongside SIGA.

TypeEmerging player
Description

Chimerix is developing temovex (another smallpox antiviral) and previously pivoted from broader antivirals to focus on orthopoxvirus countermeasures, positioning it as a future direct competitor to TPOXX in government stockpiles and treatment indications.

TypeBroad incumbent
Description

GSK is a global vaccines leader with extensive biodefense and pandemic preparedness partnerships with governments and multilateral organizations, addressing overlapping infectious-disease stockpiling customers and competing for similar procurement budgets.

TypeBroad incumbent
Description

Merck supplies ACAM2000's manufacturing infrastructure partner and operates a major vaccines/biodefense business, including government stockpiling relationships. It represents the large-pharma incumbent competing for the same biodefense procurement budgets.

TypeDirect peer
Description

Bavarian Nordic is the leading smallpox/mpox vaccine manufacturer (JYNNEOS/Imvanex/Imvamune) and a direct counterpart to SIGA in global smallpox preparedness, often procured together by the same government stockpilers. Both companies compete for the same biodefense budget pool across U.S. and allied stockpiles.

TypeEmerging player
Description

Tonix is developing TNX-801, a live-virus smallpox-prevention vaccine, and pursuing government biodefense contracts. It overlaps with SIGA in serving the same U.S. and allied smallpox preparedness procurement market with a vaccine-based alternative.

TypeBroad incumbent
Description

Moderna's mRNA platform has been applied to orthopoxvirus vaccine candidates (mRNA-1769 for mpox/smallpox). It is a broad incumbent with the platform scale to enter the same biodefense vaccine/antiviral preparedness market that SIGA serves.

TypeEmerging player
Description

BioCryst develops small-molecule antivirals (e.g., oral antivirals for influenza) and has explored biodefense-adjacent indications, making it a comparable specialty antiviral developer pursuing government and public health customers with similar regulatory pathways.

TypeOthers
Description

PPD (now part of Thermo Fisher) is a contract research organization supporting antiviral and vaccine clinical development. SIGA's CEO previously led its biopharma business, and PPD provides adjacent services in the regulatory and clinical pathway SIGA used (FDA Animal Rule) to develop TPOXX.

TypeBroad incumbent
Description

Emergent BioSolutions is a broad biodefense incumbent supplying the Strategic National Stockpile with anthrax and smallpox vaccines (ACAM2000) and other medical countermeasures. It competes with SIGA for BARDA funding across the same U.S. stockpiling budget envelope.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SIGA Technologies

Specialty Pharmaceuticals (Antiviral Therapeutics)siga.com

SIGA Technologies is a publicly traded pharmaceutical company that develops TPOXX (tecovirimat), the first FDA-approved antiviral for smallpox, and sells it primarily through government procurement contracts with BARDA, the U.S. Department of Defense, and biodefense agencies in 30+ countries.

What SIGA Technologies does

SIGA Technologies is a publicly traded (NASDAQ: SIGA) specialty pharmaceutical company developing antiviral therapeutics for orthopoxvirus infections, with TPOXX (tecovirimat) as its sole commercial asset. TPOXX is a small-molecule antiviral that inhibits the VP37 envelope protein found on all orthopoxviruses, preventing viral particles from exiting infected cells and allowing the immune system to clear the virus. The drug was developed under the FDA's Animal Rule pathway because human efficacy trials are ethically impossible for eradicated diseases, and received Orphan Drug and Fast Track Designation; TPOXX was the first FDA-approved antiviral for smallpox (2018) and is approved across the U.S., Canada, EU/UK, and Japan under the brands TPOXX, Tecovirimat SIGA, and TEPOXX. Pipeline extensions include a post-exposure prophylaxis indication (DoD-funded) and a pediatric liquid suspension (BARDA-funded).

SIGA operates as a biodefense and public health company with a direct-to-government go-to-market model. Revenue is generated almost entirely through negotiated procurement contracts with national governments and their biodefense agencies, principally BARDA and the U.S. Strategic National Stockpile under Project BioShield, the U.S. Department of Defense, and international government customers across more than 30 countries. FY2025 revenue was approximately $95 million (down from ~$139M in 2024), with $88M in product sales, $23.3M in net income, and a $155M cash position with no debt; product launches are regulatory events rather than commercial marketing efforts. The company's economics are driven by multi-year procurement cycles, special cash dividends, and incremental development funding, with corporate operations in New York and R&D in Corvallis, Oregon, and a lean headcount of approximately 50 employees.

SIGA Technologies firmographics

Firmographics
Name
SIGA Technologies
Legal name
SIGA Technologies, Inc.
Website
https://siga.com
Company type
Public
Founded year
1995
Operating status
Operating
Headcount range
51–100 employees
Short description
SIGA Technologies is a publicly traded pharmaceutical company that develops TPOXX (tecovirimat), the first FDA-approved antiviral for smallpox, and sells it primarily through government procurement contracts with BARDA, the U.S. Department of Defense, and biodefense agencies in 30+ countries.
Ownership category
akta.pro rank

SIGA Technologies industry classification

Industry
Product category
Specialty Pharmaceuticals (Antiviral Therapeutics)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYBPADAIAB
Immunization & Vaccine Delivery Programs
SECONDARYHLAJAHAK
Funding, Reimbursement & Vaccines-for-Children (VFC)/Public Purchase Programs
Healthcare & Life Sciences/Public Health, Government & Regulators/Immunization Programs & Vaccine Administration

Keywords

  • Smallpox antiviral treatment
  • Biodefense medical countermeasures
  • Orthopoxvirus therapeutics
  • Government pharmaceutical procurement
  • Antiviral drug development

Where SIGA Technologies is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

SIGA Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

  1. U.S. Government Procurement: Primary revenue source from U.S. government contracts, particularly BARDA. The company delivered remaining BARDA orders worth $26 million in 2026, with development funding of $27 million added during 2025.
  2. International Government Sales: Product sales to international governments and NGOs across 30+ countries. In January 2026, the company received a $13 million procurement order from an Asia Pacific customer under a multi-year contract.
  3. Special Cash Dividends: The company distributes special cash dividends to shareholders, having declared $0.60 per share dividend payable in April 2026, consistent with prior year distributions.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractGovernment procurement contracts - pricing negotiated through government contracting processes

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

SIGA Technologies product offering

Product offering

Core offering

SIGA Technologies develops and commercializes TPOXX (tecovirimat), the first FDA-approved antiviral for the treatment of smallpox, available in oral capsule and intravenous formulations. The company also develops pipeline indications including post-exposure prophylaxis (PEP) and a pediatric liquid suspension formulation, with development funded by U.S. government agencies such as BARDA and the Department of Defense.

Product overview

SIGA Technologies operates a single commercial product franchise: TPOXX (tecovirimat), a highly targeted antiviral that prevents orthopoxvirus particles from exiting infected cells. The franchise includes two approved formulations—Oral TPOXX capsules (FDA approved 2018) and TPOXX Injection IV (FDA approved 2018)—marketed under regional brand names: Tecovirimat SIGA in the EU/UK and TEPOXX in Japan. SIGA is advancing pipeline development for post-exposure prophylaxis (PEP) indication and a pediatric liquid suspension formulation for children weighing under 13 kg, both funded in partnership with U.S. government agencies (DoD and BARDA).

Differentiator

Problem solved

Functional benefit

Brands

  • TPOXX® (tecovirimat): First FDA-approved antiviral treatment for smallpox; available in oral and IV formulations. Treats smallpox, mpox, cowpox, and vaccinia complications in approved markets.

Products and services

  • TPOXX (Oral Tecovirimat Capsules) First FDA-approved oral antiviral for the treatment of smallpox and related orthopoxvirus infections in adults and pediatric patients weighing at least 13 kg. Marketed under regional brand names Tecovirimat SIGA in the EU and TEPOXX in Japan.
  • TPOXX Injection (IV) Intravenous formulation of tecovirimat approved by the FDA for the treatment of smallpox in patients weighing at least 3 kg who cannot swallow oral capsules.
  • TPOXX Post-Exposure Prophylaxis (PEP) Investigational use of TPOXX as a post-exposure prophylaxis for adults exposed to smallpox, in development with U.S. Department of Defense funding and support.
  • TPOXX Pediatric Liquid Suspension Oral liquid suspension formulation of TPOXX being developed for the treatment of smallpox in pediatric patients weighing less than 13 kg, funded in collaboration with BARDA.

Quantifiable outcome

  • Over $1 billion in cumulative government procurement orders
  • +3 more outcomes

Companies that use SIGA Technologies

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

SIGA Technologies technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

SIGA Technologies partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development PartnerPrimary strategic partner providing funding and support for TPOXX development. BARDA has supported advanced development of TPOXX under the U.S. Department of Health and Human Services. In 2025, the BARDA contract was modified to add $27 million in development funding. Remaining orders worth $26 million expected to be delivered in 2026.
  • U.S. Department of DefensecoreStrategic or Co-development PartnerPartner funding and supporting the post-exposure prophylaxis (PEP) development program for TPOXX. The DoD collaboration focuses on developing TPOXX as a treatment for adults exposed to smallpox.
  • Healthcare Professionals and GovernmentscoreStrategic or Co-development PartnerSIGA collaborates with healthcare professionals, governments, and communities to minimize the spread and impact of infectious disease outbreaks. The company has established partnerships with over 30 countries and numerous organizations for smallpox outbreak response.
  • FDA (U.S. Food and Drug Administration)coreStrategic or Co-development PartnerRegulatory partnership for TPOXX development under the FDA's Animal Rule pathway. FDA granted TPOXX Fast Track Designation and Orphan Drug Designation. TPOXX was the first FDA-approved antiviral for smallpox treatment.
  • Strategic National Stockpile (SNS)coreStrategic or Co-development PartnerThe U.S. government has relied on TPOXX treatment for over a decade to equip the Strategic National Stockpile against potential smallpox outbreaks under Project BioShield.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

SIGA Technologies competitors and assessment

Company assessment

Broad incumbents

  • Sanofi: Sanofi operates a global vaccines franchise and has biodefense and public health partnerships across multiple governments, addressing overlapping stockpiling customers in smallpox, mpox, and broader infectious-disease preparedness alongside SIGA.
  • GSK: GSK is a global vaccines leader with extensive biodefense and pandemic preparedness partnerships with governments and multilateral organizations, addressing overlapping infectious-disease stockpiling customers and competing for similar procurement budgets.
  • Merck & Co. Merck supplies ACAM2000's manufacturing infrastructure partner and operates a major vaccines/biodefense business, including government stockpiling relationships. It represents the large-pharma incumbent competing for the same biodefense procurement budgets.
  • Moderna: Moderna's mRNA platform has been applied to orthopoxvirus vaccine candidates (mRNA-1769 for mpox/smallpox). It is a broad incumbent with the platform scale to enter the same biodefense vaccine/antiviral preparedness market that SIGA serves.
  • Emergent BioSolutions: Emergent BioSolutions is a broad biodefense incumbent supplying the Strategic National Stockpile with anthrax and smallpox vaccines (ACAM2000) and other medical countermeasures. It competes with SIGA for BARDA funding across the same U.S. stockpiling budget envelope.

Emerging players

  • Chimerix: Chimerix is developing temovex (another smallpox antiviral) and previously pivoted from broader antivirals to focus on orthopoxvirus countermeasures, positioning it as a future direct competitor to TPOXX in government stockpiles and treatment indications.
  • Tonix Pharmaceuticals: Tonix is developing TNX-801, a live-virus smallpox-prevention vaccine, and pursuing government biodefense contracts. It overlaps with SIGA in serving the same U.S. and allied smallpox preparedness procurement market with a vaccine-based alternative.
  • BioCryst Pharmaceuticals: BioCryst develops small-molecule antivirals (e.g., oral antivirals for influenza) and has explored biodefense-adjacent indications, making it a comparable specialty antiviral developer pursuing government and public health customers with similar regulatory pathways.

Direct peers

  • Bavarian Nordic: Bavarian Nordic is the leading smallpox/mpox vaccine manufacturer (JYNNEOS/Imvanex/Imvamune) and a direct counterpart to SIGA in global smallpox preparedness, often procured together by the same government stockpilers. Both companies compete for the same biodefense budget pool across U.S. and allied stockpiles.

Others

  • Pharmaceutical Product Development (PPD / Thermo Fisher): PPD (now part of Thermo Fisher) is a contract research organization supporting antiviral and vaccine clinical development. SIGA's CEO previously led its biopharma business, and PPD provides adjacent services in the regulatory and clinical pathway SIGA used (FDA Animal Rule) to develop TPOXX.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

SIGA Technologies social profiles

Digital presence

SIGA Technologies compliance and trust

Trust signal

Compliance3 records

SIGA Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SIGA Technologies leadership team

Management profile

Number of profiles

Profiles4 records

SIGA Technologies funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SIGA Technologies M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SIGA Technologies

What does SIGA Technologies do?

SIGA Technologies develops and commercializes TPOXX (tecovirimat), the first FDA-approved antiviral for the treatment of smallpox, available in oral capsule and intravenous formulations. The company also develops pipeline indications including post-exposure prophylaxis (PEP) and a pediatric liquid suspension formulation, with development funded by U.S. government agencies such as BARDA and the Department of Defense.

Is SIGA Technologies a public or private company?

SIGA Technologies is a public company. It is classified as public and is currently operating.

When was SIGA Technologies founded?

SIGA Technologies was founded in 1995. It employs 51 to 100 people.

Where is SIGA Technologies based?

SIGA Technologies is headquartered in New York, United States, in the North America region.

How does SIGA Technologies make money?

Three revenue lines are on record. U.S. Government Procurement is the primary driver. The others are international Government Sales and special Cash Dividends.

Who are SIGA Technologies's main competitors?

Broad incumbents on record are Sanofi, GSK, Merck & Co., Moderna and Emergent BioSolutions. Emerging players are Chimerix, Tonix Pharmaceuticals and BioCryst Pharmaceuticals. Bavarian Nordic is listed as a direct peer. Pharmaceutical Product Development (PPD / Thermo Fisher) is listed as an others.

Does SIGA Technologies have an API?

No public API is recorded for SIGA Technologies.

What industry is SIGA Technologies in?

SIGA Technologies's product category is Specialty Pharmaceuticals (Antiviral Therapeutics). Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAK, Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldFinancial Review: Vanda Pharmaceuticals (NASDAQ:VNDA) vs. Siga Technologies (NASDAQ:SIGA)Vanda Pharmaceuticals and Siga Technologies are compared on profitability, analyst ratings, and institutional ownership. Vanda has a lower beta, negative net margin, and a consensus price target of $13.50, while Siga has positive net margin but lower revenue. Analysts favor Vanda with a higher rating score and upside.YahooSIGA Technologies Inc (SIGA) (Q3 2026) Earnings Call Highlights: New Canada Contract, $116 ...SIGA Technologies reported Q3 2026 net loss of $3 million and no product sales, with product revenue of $42 million for nine months. The company holds $116 million in cash and no debt, and signed a five-year Canada DND contract for oral TPOXX up to $15 million. It expects Phase 1 pediatric results by year-end and a supplemental NDA filing in 2028.Seeking AlphaSIGA Technologies, Inc. (SIGA) Q3 2026 Earnings Call TranscriptSIGA Technologies held its Q3 2026 earnings call on November 9, 2026, with CEO Diem Nguyen and CFO Dan Luckshire. The company reported completing its final product delivery under the BARDA 19C contract in Q2, fulfilling all obligations. SIGA remains committed to deploying its smallpox therapeutic TPOXX for rapid large-scale deployment if an outbreak occurs.The future of tradingSIGA Technologies Presents TPOXX Growth Strategy Focused on Expanded Uses and Global AccessSIGA Technologies is targeting a new TPOXX contract with the U.S. Strategic National Stockpile, following two prior BARDA procurements totaling $1.007 billion. The company reported $680 million in product revenue and $395 million in pretax operating income from 2020-2025, with $116 million in cash and no debt.Investing.comEarnings call transcript: SIGA’s Q3 2026 loss offsets Canada contract gainsSIGA Technologies reported a Q3 2026 loss of $0.04 per share on $1.3 million in revenue, with no product sales that quarter. The company highlighted a new Canadian defense contract worth up to $15 million over five years, and ended the quarter with $116 million in cash and no debt. Management expects Phase I pediatric formulation results by year-end 2026.The future of tradingSIGA Technologies’ three-month net loss narrows 55% to $2.89 millionSIGA Technologies reported a three-month net loss of $2.89 million for the quarter ended September 30, 2026, a 55% year-over-year narrowing. Total revenues fell 50% to $1.32 million. The company awarded a Canadian defence contract covering up to $15 million of oral TPOXX, including $9 million in firm commitments.The future of tradingSIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.SIGA Technologies announced that Chief Scientific Officer Dennis Hruby will retire effective today, concluding over 30 years with the company. He led the development of TPOXX, the first antiviral for smallpox, which has been sold to over 30 countries. Hruby will continue in an advisory capacity.YahooSIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.SIGA Technologies announced that Chief Scientific Officer Dennis Hruby will retire effective today, concluding over 30 years with the company. He led the development of TPOXX, the first FDA-approved antiviral for smallpox, which has been sold to over 30 countries. Hruby will continue in an advisory capacity.Business & FinancialSIGA Announces Retirement Of Chief Scientific Officer Dennis Hruby, Ph.D.SIGA Technologies announced that Chief Scientific Officer Dennis Hruby will retire effective today, ending over 30 years with the company. He led the development of TPOXX, the first antiviral for smallpox, approved in 2018 and 2022. He will continue in an advisory capacity.Business & FinancialSIGA Reports Financial Results For Three And Nine Months Ended September 30, 2026SIGA reported Q3 2026 net loss of $2.9 million and Q3-9 net income of $6.1 million, with total revenues of $1.3 million and $48.6 million respectively. The company delivered $13 million of oral TPOXX and $26 million of IV TPOXX to customers, and a Canadian contract for up to $15 million was awarded.